UBS’s Akebia Therapeutics AKBA Stock Holding History

UBS’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$738K	Buy	33,318 +16,587	+99%	+$381K	﹤0.01%	3880
2014 Q2	$465K	Buy	+16,731	New	+$403K	﹤0.01%	4292

Other funds holding AKBA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

UBS's AKBA Position: Q3 2014 in Review

UBS increased its Akebia Therapeutics (AKBA) stake by 99% in Q3 2014, buying an estimated $381K and bringing the position to 33,318 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #3880.

UBS first reported a position in AKBA in Q2 2014 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold AKBA as of Q3 2014.

UBS held 33,318 shares of Akebia Therapeutics worth $738K as of Q3 2014.
UBS bought 16,587 Akebia Therapeutics shares in Q3 2014, an estimated $381K.
Akebia Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3880 holding.
UBS first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 2 quarters since.
51 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.